Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Joseph P. Hagan Acquires 50,000 Shares of Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Joseph P. Hagan purchased 50,000 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were purchased at an average cost of $1.09 per share, for a total transaction of $54,500.00. Following the transaction, the chief executive officer now owns 260,808 shares of the company’s stock, valued at $284,280.72. This trade represents a 23.72 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Regulus Therapeutics Price Performance

Regulus Therapeutics stock opened at $1.00 on Friday. The stock has a 50 day moving average of $1.46 and a two-hundred day moving average of $1.54. Regulus Therapeutics Inc. has a twelve month low of $0.83 and a twelve month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Creative Planning purchased a new stake in Regulus Therapeutics in the 3rd quarter valued at approximately $26,000. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics in the 3rd quarter valued at approximately $33,000. Jane Street Group LLC purchased a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $46,000. JPMorgan Chase & Co. grew its holdings in Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 52,059 shares during the period. Finally, Barclays PLC raised its position in Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 62,549 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.